By Dr John Comley After nearly 15 years of challenging maturity 1536 plate adoption (particularly in primary screening), finally appears to have taken hold. There is now available a broad range of 1536 plate types; an ever expanding variety of tools that make most assays types and profiling approaches doable… Read More
By Dr Susanta K. Sarkar The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment management of targeted therapies. Read More
Share Share Tweet Email Stem Cell Therapies: Assessing the commercial opportunity Stem Cell Therapies: Assessing the commercial opportunity By Su Webber, Andrew Millest and Mark Williams Restructuring and reorganisation is routine and relentless in the pharmaceutical industry, with a future focus essential for effective strategic decision making. In recent years,… Read More
Early Validation: The difference between success and failure? By Mike Benevento and Victor Bornsztejn Validation is typically associated with drug production and manufacturing, and often considered not to impact drug discovery and development. In fact, this assumption is not true and despite the fact that early-stage research may not require… Read More
High Throughput Screening, High Content Screening, Primary and Stem Cells By Dr Richard M. Eglen Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies. Furthermore, a wide… Read More
Livening up HCS Imaging By Dr John Comley With the aid of recent end-user feedback, this article investigates interest in and use of live cell and kinetic HCS imaging; most wanted application areas: advantages of live cell HCS imaging; live cell HCS assays of greatest interest; what's limiting live cell… Read More
High Content Screening - The next challenge: effective data mining and exploration By Dr Kurt Zingler and Dr Stephan Heyse The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount. Over the… Read More
By Dr Anil Vasudevan Since the original publications on the benefits of conducting organic reactions in a microwave by Gedye (1) and Majetich (2) in the mid-80s, the uptake of this technique was sluggish at best for the next 12-14 years. However, the past few years have witnessed an explosion… Read More
High Throughput Screening in Academia - Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in developing tool molecules… Read More
Growing Interest in Outsourcing Ion Channel Services By Dr John Comley Summer 2008 Significant demand now exists in Pharma and Biotech to access ion channel testing services and this is reflected by the number and the variety of service offerings. In the highly competitive area of cardiac safety hERG testing… Read More
Progress in the Implementation of Label-Free Detection - Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec's recent Cell-Based Label-Free Detection Trends report. Uniquely all of these label-free offerings are plate-based and… Read More
Screening the Human Kinome - Expectations Met or Promises Pending? By Dr Richard M. Eglen Protein kinases are important targets in drug discovery programmes aimed at treating cancer, autoimmune disorders, diabetes and neurological disorders. Novel information on kinase biology is opening up other approaches in the design of selective inhibitors… Read More
The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers to scientists… Read More
Dispense and Imaging Assays - Moving towards a more balanced use of both fluorescence and flash luminescent readouts By Dr John Comley Progress towards the uptake and adoption of flash luminescence readouts in screening were the subject of HTStec's recent Dispense & Imaging (D&I) Trends 2007 report. The report suggests… Read More
Needs and challenges in High Throughput Screening By William Downey, Dr Helen Nicely and Dr Lynne Sopchak High throughput screening (HTS) groups face similar challenges as the pharmaceutical and biotechnology industry as a whole faces. HTS groups are looking for ways to improve effectiveness in lead discovery, increase their productivity… Read More
William Downey and Dr Shauna Farr-Jones GPCRs are the most studied drug target class and have a proven record as valuable drug targets, with 40-50% of marketed drugs being modulators of GPCR function. Despite the intense effort focused on these targets by the pharmaceutical industry over many years, numerous challenges… Read More